
A real-world data study reveals that Black prostate cancer patients on androgen deprivation therapy (ADT) experience lower risks of major adverse cardiovascular events (MACE) and all-cause mortality compared to White patients, challenging previous findings that suggested racial disparities in outcomes.
Like
Save
Share